Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022
November 07 2022 - 7:01AM
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical
company engaged in the commercialization and development of
innovative anti-infective agents to treat serious infections, today
announced that it will report its third quarter financial results
along with recent company highlights after the close of the U.S.
financial markets on Thursday, November 10, 2022. Nabriva’s
management will host a conference call at 4:30 p.m. ET to discuss
the financial results and recent corporate highlights.
The dial-in number for the conference call is 833-634-2311 for
domestic participants and 412-902-4177 for international
participants and ask to join the “Nabriva Therapeutics’ Conference
Call”. A live webcast of the conference call can be accessed
through the “Investors” tab on the Nabriva Therapeutics website at
www.nabriva.com. A replay will be available on this website shortly
after conclusion of the event for 90 days.
About Nabriva Therapeutics plc
Nabriva Therapeutics is a biopharmaceutical
company engaged in the commercialization and development of
innovative anti-infective agents to treat serious infections.
Nabriva Therapeutics received U.S. Food and Drug Administration
approval for XENLETA® (lefamulin injection, lefamulin tablets), the
first systemic pleuromutilin antibiotic for community-acquired
bacterial pneumonia (CABP). Nabriva Therapeutics is also developing
CONTEPO™ (fosfomycin) for injection, a potential first-in-class
epoxide antibiotic for complicated urinary tract infections (cUTI),
including acute pyelonephritis. Nabriva entered into an exclusive
agreement with subsidiaries of Merck & Co. Inc., Kenilworth,
N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid
phosphate) in the United States and certain of its territories.
Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Nabriva Therapeutics, including but not
limited to statements about the timing and effectiveness of the
reverse stock split and Nabriva Therapeutics’ ability to satisfy
Nasdaq’s continued listing standards and other statements
containing the words “anticipate,” “believe,” “estimate,” “expect,”
“intend,” “may,” “plan,” “predict,” “project,” “target,”
“potential,” “likely,” “will,” “would,” “could,” “should,”
“continue,” and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including: Nabriva Therapeutics’ ability to
successfully execute its commercialization plans for XENLETA and
SIVEXTRO and whether market demand for XENLETA and SIVEXTRO is
consistent with its expectations, Nabriva Therapeutics’ ability to
build and maintain a sales force for XENLETA and SIVEXTRO, the
content and timing of decisions made by the U.S. Food and Drug
Administration and other regulatory authorities, the uncertainties
inherent in the initiation and conduct of clinical trials,
availability and timing of data from clinical trials, whether
results of early clinical trials or studies in different disease
indications will be indicative of the results of ongoing or future
trials, uncertainties associated with regulatory review of clinical
trials and applications for marketing approvals, the availability
or commercial potential of CONTEPO for the treatment of cUTI, the
extent of business interruptions resulting from the COVID-19
pandemic or similar public health crises, the ability to retain and
hire key personnel, the availability of adequate additional
financing on acceptable terms or at all and such other important
factors as are set forth in Nabriva Therapeutics’ annual and
quarterly reports and other filings on file with the U.S.
Securities and Exchange Commission. In addition, the
forward-looking statements included in this press release represent
Nabriva Therapeutics’ views as of the date of this press release.
Nabriva Therapeutics anticipates that subsequent events and
developments will cause its views to change. However, while Nabriva
Therapeutics may elect to update these forward-looking statements
at some point in the future, it specifically disclaims any
obligation to do so. These forward-looking statements should not be
relied upon as representing Nabriva Therapeutics’ views as of any
date subsequent to the date of this press release.
CONTACTS:
For InvestorsKim AndersonNabriva Therapeutics
plcir@nabriva.com
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Apr 2024 to May 2024
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From May 2023 to May 2024